-
2013.12.11
- Launch of Abstral® sublingual tablets for Cancer Pain Treatment in Japan
-
2013.11.05
- Noven Pharmaceuticals, Inc. press release :First and Only FDA-approved, Non-Hormonal Treatment for Moderate to Severe Hot Flashes Now Available by Prescription in U.S. Pharmacies
-
2013.10.09
- FY02/2014 Q2 Results Earnings Release Presentation
-
2013.10.01
- Notice of Revision of Financial Forecast
-
2013.09.20
- Announcement regarding the Marketing Approval of Abstral® sublingual tablets for Cancer Pain Treatment
-
2013.09.19
- Noven Pharmaceuticals, Inc. press release :Menopause Publishes Pivotal Trial Results for Brisdelle™ (Paroxetine) Capsules, an FDA-Approved Non-Hormonal Therapy for Vasomotor Symptoms Associated with Menopause
-
2013.09.11
- Notification on the commencement of Phase II clinical study of HP-3000 in Japan (a transdermal drug for the treatment of idiopathic restless legs syndrome)
-
2013.08.30
- Notification about the application for a partial change (Public knowledge-based application) to the approval items of the estradiol transdermal patch Estrana® Tape 0.72 mg
-
2013.07.31
- Notification of submission of supplemental new drug application (NDA) for the addition of indication for chronic pain on the transdermal, long-acting cancer pain relief patch FENTOS® TAPE (development code: HFT-290)
-
2013.07.23
- Noven Pharmaceuticals, Inc. press release :Noven announces positive Phase 2 results of investigational d-Amphetamine Transdermal System for ADHD
-
2013.07.10
- Press Release related to the initiation of Phase 2 clinical study on HP-3060 (a transdermal long-acting system for the treatment of allergic rhinitis)
-
2013.07.10
- FY02/2014 Q1 Results Earnings Release Presentation
-
2013.07.01
- Noven Pharmaceuticals, Inc. press release :Noven Receives FDA Approval for Brisdelle™ (Paroxetine) Capsules, the First Nonhormonal Therapy for Vasomotor Symptoms Associated with Menopause
-
2013.05.24
- Announcement of listing on the NHI drug price standard and marketing of NEOXY® Tape 73.5 mg, transdermal overactive bladder treatment medication
-
2013.05.14
- Notification of the results of the Phase II clinical study in the United States of HTU-520 (terbinafine hydrochloride patch), a therapeutic agent for tinea unguium.
-
2013.04.11
- FY02/2013 Q4 Results Earnings Release Presentation
-
2013.04.11
- Announcement of Change in Executives
-
2013.04.04
- Noven Pharmaceuticals, Inc. press release :Noven confirms filing of Abbreviated New Drug Application for generic version of Exelon® (rivastigmine transdermal system)
-
2013.03.28
- Notice Regarding Change in the Board of Directors
-
2013.03.28
- Board Personnel
-
2013.03.25
- Notification of the approval of a production and sales permit for NEOXY®Tape 73.5mg, overactive bladder treatment medication (oxybutynin hydrochloride, transdermal therapeutic formulation, development code: HOB-294)
-
2013.03.08
- Notification on the results of the phase III clinical study in Japan for the addition of efficacy for “chronic pain” using the transdermal, long-acting cancer pain relief patch FENTOS® TAPE (development code: HFT-290)
-
2013.03.06
- Noven Pharmaceuticals, Inc. press release :Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
-
2013.01.10
- FY02/2013 Q3 Results Earnings Release Presentation
-
2013.01.07
- Notice Pertaining to the Joint Distribution of Transdermal Pain Reliever and Anti-Inflammatory Mohrus®Pap 30mg and Mohrus®Pap 60mg
